Lexaria Bioscience Corporation (LEXX) Quote

YEP! You look away for a few minutes eom

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
Kelowna, British Columbia – April 30, 2024 – TheNewswire –Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has entered into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants to purchase an aggregate 2,917,032 shares of its common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share, originally issued in October 2023 and February 2024, respectively.

With this exercise, there are zero remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. The gross proceeds to the Company from the exercise are expected to be approximately $4.7 million, prior to deducting estimated offering expenses.

In consideration for the early exercise of the existing warrants for cash, and the payment of $0.125 per each new warrant, aggregating $364,629 in proceeds to the Company, Lexaria is issuing 2,917,032 new warrants, each new warrant entitling the holder to purchase one (1) new share of common stock. The new warrants are immediately exercisable at an exercise price of $4.75 per share, and will expire on February 16, 2029 if not exercised before that date.

The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

“These additional cash proceeds of $4.7 million further extend Lexaria’s operational runway deep into 2025 and allow us to execute our 2024 plans at an aggressive pace,” said Chris Bunka, CEO of Lexaria. “The exercise price of the replacement warrants, at $4.75, is a significant premium to current market prices and, in our opinion, a sign of confidence in Lexaria’s future.”

The new warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of Class A common stock issuable upon exercise of the new warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the new warrants issued in the private placement and the shares of common stock underlying the new warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issuable upon the exercise of the new warrants.

In connection with the issuance of the new warrants, Lexaria is required to provide H.C. Wainwright with its tail consideration of 6% of the cash proceeds received for the warrant exercises and issuance of the new warrants and to issue 102,097 warrants with an exercise price of $5.9375 per share and having the same terms and conditions as the new warrants.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations

Eli Lilley share price is soaring as their GLP-1 drug flies off the shelves! Just imagine if it could be orally administered with DHT!

Wow! You look away for a few minutes and the stock jumps over 20%.

Target Price: $8

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_04292024_LEXX_Vandermosten.pdf

https://www.msn.com/en-ca/money/companies/big-pharma-s-dogfight-to-dominate-the-anti-obesity-market/ar-AA1nMUoM?ocid=msedgdhp&pc=U531&cvid=cadf8bfbc47b4e9588b5d206a04fca0d&ei=48

https://letstoke.us19.list-manage.com/track/click?u=f2e0706764f99154e3a11feb5&id=eda1810eb7&e=9cbb5a4bc7

I think he's mistaken about the hypertension trial being underway, they have FDA approval but I don't believe it's started.

https://letstoke.us19.list-manage.com/track/click?u=f2e0706764f99154e3a11feb5&id=cdea306711&e=9cbb5a4bc7
Lexaria Bioscience (NASDAQ: LEXX): dipped to $2.12 last week which is a market cap of $27 million.
On March 12, 2024, as LEXX was rallying strongly, I said I didn’t think LEXX’s market cap would fall
below $30 million and last week it did. Remember, LEXX has a hypertension solution approved by the
FDA for additional testing that is underway with early results expected shortly. It also has a diabetes/obesity that is probably a year from gaining FDA testing approval. There should be several results
oriented news releases this year. These are two potentially major projects, either one of which can
justify a $30 million market cap. As LEXX falls back, it gives investors a second chance to grab the ring.
If I believed LEXX was attractive at $3, I like it even more at around $2. I conclude that LEXX has the
potential to rally back strongly.

https://ir.lexariabioscience.com/news-events/press-releases/detail/246/lexaria-receives-ethics-review-board-approval-to-begin-new

JUST A MILK MACHNE FOR BUMKO AND DR DEATH -- $600K PLUS PER YR FOR THE DUO SALARY THAT MADE THIS A R &D DISASTER SINK HOLE

60% haircut in a month from highs of $6
.85, not bad.
If it consolidated around 3, will go to 25 to 3 in the next major news

Back to $70/sh !! Sounds good. Make it happen. lol

Still accept that last post provided it consolidates around 4 pps

But it seems someone is flooding mkt without shares or.shorts.have got it and just taking it back to where.it all started

May I remind you of your last post 3 weeks ago..
"The next leg up will be 5-8 million daily volume and price, which is going 300-400%from these levels".
Something is wrong with your calculations making it a bit hard to trust them!

Going back to 0.65

https://mailchi.mp/lexariabioscience.com/lexaria-awarded-new-patents?e=aa4bd7bcad

https://www.biospace.com/article/wegovy-cardiovascular-approval-furthers-march-into-new-indications/

Huge for the sector and for a potential pill or sublingual version with few, if any, side effects.

https://www.nbcnews.com/health/health-news/medicare-will-cover-wegovy-reduce-heart-disease-risk-rcna143479

Yes and bought by people who see an this as a value entry point. What's that saying :), Be greedy when others are fearful and be fearful when others are greedy.

The next leg up will be 5-8 million daily volume and price, which is going 300-400%from these levels.

I am waiting on some big pharma or bug tobacco partnership that will take to 20 to 30x

That can happen anytime between now and year end

and it's still being bought as it does!

It may be much ado about nothing, but it's still selling off

Lexaria’s Shakespearian Correction – Much Ado About Nothing
https://www.letstoke.biz/_files/ugd/449582_f3c7ffb8161b40a1a2cd3dc4651cd1df.pdf

Needs a delivery system. DehydraTECH?
https://www.msn.com/en-ca/health/other/revealed-cannabis-deadly-effect-on-melanoma-skin-cancer-cells-new-study-finds/ar-BB1jnVEa?ocid=msedgntp&pc=DCTS&cvid=75143799a3684685955138ffe187c061&ei=24

https://ir.lexariabioscience.com/news-events/press-releases/detail/244/lexaria-appoints-nelson-cabatuan-as-chief-financial-officer

I’d do dirty, dirty things for that salary… just saying

BUMKA GETS A $1000 A DAY (including weekends) FOR DOING soft piece on access wire or BS lunch with ted O --I ' LL TAKE THE JOB FOR HALF THAT AND SO WILL MANY OTHERS

Executive compensation is obviously on our backs as well as studies and patents etc. but IMO the pros outdo the cons and that's why I'm still here. It's easy to imagine we're not getting enough bang for our bucks until we get proven otherwise. I like to think: Would I like to do Bunka's job for the amount he gets paid and the answer is a huge "No"! You couldn't pay me enough because I'm sure he has sacrificed a lot in his personal life. I'm okay with the amount our leaders are taking as I can see progress. I wish it was faster but gotta stay patient if I want to land some Big Pharma bucks!

46.25%

Any idea what executive compensation is tied to? Seems that’s more what the investors are supporting by helping to absorb the warrants etc?

its a green day -- i am happy for that glta

This is typical for an R&D company that doesn't have much revenue. Hopefully everyone's averaged down enough they can absorb supporting the company as you mentioned.

It's also pretty clear that LEXX is funding its research off the backs of investors. They make money every single time these large warrants are sold and they use it for funding.

This is not fraud, but it's also doesn't give stock holders a good feeling. Some have waited for years for this stock to go up.

I have done my due diligence and then I came across this board. I am just trying to get an idea of what everyone is going through.

LEXX does not commit fraud or they would be quickly out of business. You can't trust posters on these online bull boards to tell the truth. Everyone has their own agenda. Think about how the individual posts might benefit the individual if taken as verbatim! Read between the lines and Do Your own Due Diligence through other sources besides the bull boards. Good Luck.

What are you going to do? Did you sell? Sorry to hear about that loss man...

This stock seems to be fraught with fraud.

How can you say it's been going up slowly?? It literally sky rocketed the past few weeks.

Can you catch me up to pace... I've been just checking out LEXX and there is years of comments talking about fraud and that type of stuff...

Can you explain exactly what you mean? I'm new to LEXX and just trying to catch up. Literally years of posts of whats going on. Can you give me a summary? Are you in the stock?

I'm all new to this LEXX. I've been reading through what you guys have been through in the last few years with LEXX issuing warrants and the pump and dumps.

Many of your posts like a year ago, were talking about how LEXX was stealing from shareholders through these warrants

Can anyone give more information? Should we stay in this stock or not? Seems like a lot of fraud and mismangment going on but we can all see the patents and future prospects of LEXX

Can anyone provide me some insight?

I just read through the S-1 just issued and I don't see where it says the warrants have been exercised. Not that they haven't been. I'm not sure how you know this. Could you provide a link of some sort? Also, where is it written in the offering or elsewhere that exercised warrants have a 6 month holding period. Not trying to argue...just want to understand this. Thanks.

Warrants exercised have a holding period of 6 months
1.6 mil warrants have been exercised

I call it an amazing gift from the short sellers to anyone wishing to get in for the first time or add to their positions!

Yep. The hawks have all been waiting for a chance to pump comments. Rest and we'll see about resume.

just look. at the numbers not my post-- but something is wrong here